Express News | AIM ImmunoTech Announces New Pre-Clinical Data Showing Ampligen As Part Of Combination Therapy Slows Melanoma Tumor Growth And Improves Survival In Mouse Model
Express News | Aim Announces New Positive Data on Ampligen’s Anti-Tumor Potential When Used as Part of a Combination Therapy
AIM Announces New Positive Data on Ampligen's Anti-Tumor Potential When Used as Part of a Combination Therapy
Express News | Todd Deutscha: Reiterates It Is Not Their Intention to Acquire Control Stake in AIM ImmunoTech's Shares of Common Stock
Express News | Todd Deutsch Says Excpect AIM ImmunoTech Board to Promptly Amend Bylaws in Way That Is Consistent With Fiduciary Duties
Express News | Todd Deutsch Says Significant Change in AIM ImmunoTech's Board Is Urgently Needed - SEC Filing
AIM ImmunoTech Files to Sell 11.28M Shares of Common Stock for Holders
Advyzon Investment Management (AIM) Partners With FINIAT to Provide Turnkey Trading and Portfolio Management
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM's Membership With ACIL Changes the Game in Lab Testing
AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series
Express News | ImmunoTech Announces Pricing Of 5,640,958 Share Registered Direct Offering At $0.363 Per Share; Gross Proceeds ~$2M
AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering
Express News | AIM ImmunoTech Inc : Ascendiant Capital Markets Raises Target Price to $5.25 From $5
Buy Rating Affirmed: AIM ImmunoTech's Ampligen Shows Promising Oncology Pipeline Progress
Q1 2024 AIM ImmunoTech Inc Earnings Call
Earnings Call Summary | AIM ImmunoTech(AIM.US) Q1 2024 Earnings Conference
AIM ImmunoTech Inc. (AIM) Q1 2024 Earnings Call Transcript
Express News | AIM ImmunoTech Inc: Qtrly Shr Loss $0.12
No Data